Today's Focus:

Micromind Neuroscience (02172.HK) announced that it expects a mid-term net income growth of about 124% to 158%.

Minimally Invasive Brain Science (02172.HK) announced that the company is expected to record a net income of approximately RMB 130 million to RMB 150 million for the six months ending June 30, 2024, which is an increase of approximately 124% to 158% compared to the six months ending June 30, 2023.

According to the current information, the board of directors believes that the aforementioned group profit growth is mainly due to the following reasons: (1) benefited from hospital coverage and market share growth, and rapid overseas business growth, the group's expected revenue for the reporting period is expected to increase by approximately 34% to 37% compared to the same period last year; (2) through the execution of multiple supply chain improvement projects and cost optimization measures, the group's operational efficiency has been improved, and profitability has been significantly enhanced.

Important event

CR Construction (01582.HK): CR Construction (United Kingdom) signed two construction contracts with a total contract amount of approximately 0.21 billion pounds.

Dynagreen Env (01330.HK) signed a cooperation framework agreement with institutions such as the Shenzhen Research Institute of Peking University.

idreamsky (01119.HK): Karapichu officially joins the Esports World Cup.

Performance of Financial Report:

Qianhai Health (00911.HK) profit announcement: expected to turn a mid-term loss into a profit.

Entertainment company Daocaoxiong (02125.HK) announced its profit forecast, expecting a year-on-year increase of approximately 2075.5%-2825.7% in comprehensive net profit attributed to shareholders for the first half of the year.

CSSC leasing (03877.HK) profit announcement: expected to increase mid-term surplus by 21% to 23%.

Oshidori Holdings (00622.HK) profit warning: expected mid-term net loss of HKD 110.7 million.

Operating Data:

Chow Tai Fook (01929.HK) first quarter retail value decreased by 20% year-on-year, with same-store sales in Mainland China and Hong Kong and Macau showing a decline.

Medical Innovation:

Shanghai Pharma (02607.HK): Approval for the production of Apixaban ethylamine tablets.

SSY Group (02005.HK): The hydrochloride of norepinephrine has been approved and registered by the Drug Administration Bureau as an active pharmaceutical ingredient for use in marketed preparations.

Acquisitions and Disposals:

Ali Pictures (01060.HK) acquired all the shares of Jialiwensheng and 70% of Dongyang Mela's shares.

rykadan capital (02288.HK) plans to acquire 100% equity of a property holding company for HKD 56.084 million.

Additional Share Issuance:

Shun Wo Group (01591.HK) plans to merge shares on a ratio of 10 to 1.

【Increase and Decrease】

Friendtimes (06820.HK): The controlling shareholder increased their shareholding by 4.086 million shares.

Repurchase cancellation.

Meituan-W (03690.HK) spent HKD 832 million to repurchase 7.015 million shares on July 23.

AIA (01299.HK) has repurchased 7.758 million shares for HKD 0.42 billion on July 23.

HSBC Holdings (00005.HK) spent 0.167 billion Hong Kong dollars on July 22 to repurchase 2.5 million shares.

Ke Holdings (02423.HK) spent 3 million dollars on July 22nd to repurchase 0.627 million shares.

Hang Seng Bank (00011.HK) spent HKD 20.29 million to repurchase 0.2 million shares on July 23.

Guangzhou Automobile Group (02238.HK) spent HKD 20 million to repurchase 6.988 million shares on July 23.

On July 22, Pru (02378.HK) spent 1.727 million British pounds to repurchase 0.2445 million shares.

Livzon Pharma (01513.HK) spent 11.959 million yuan to repurchase 0.326 million A-shares on July 23rd.

GME Group Holdings (08188.HK) cancelled 2.292 million shares on July 23.